AFC-HD AMS Life Science Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending February 2021 and Full Year Ending August 2021
January 05, 2021 at 02:15 am EST
Share
AFC-HD AMS Life Science Co., Ltd. provided consolidated earnings guidance for the six months ending February 2021 and full year ending August 2021. For the six months ending February 2021, the company expects net sales of JPY 8,000 million, operating profit of JPY 570 million, ordinary profit of JPY 570 million, profit attributable to owners of parent of JPY 370 million and basic earnings per share of JPY 26.71.
For the year ending August 2021, the company expects net sales of JPY 16,000 million, operating profit of JPY 1,100 million, ordinary profit of JPY 1,100 million, profit attributable to owners of parent of JPY 720 million and basic earnings per share of JPY 51.98.
AFC-HD AMS Life Science Co Ltd is a Japan-based company mainly engaged in the development of the healthcare business and the pharmaceutical business. The Company is engaged in the research and development, product design, manufacture and sale of health foods and cosmetics, manufacture and sale of Chinese medicine medicines, general medicines, generic medicines, healthcare products, the sale of natural foods, as well as planning of health information programs. The Company operates in two business segments. The Healthcare segment is engaged in the manufacture and sale of health foods and cosmetics, as well as the provision of original equipment manufacturers (OEM). The Pharmaceutical segment is engaged in the manufacture and sale of ethical drugs and over-the-counter drugs, as well as the sale of generic drugs. The Company is also engaged in the management of restaurants through subsidiary.
AFC-HD AMS LIFE SCIENCE CO., LTD. 
